Cost of Revenue of Pharma-Bio Serv, Inc. from 30 Apr 2017 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Pharma-Bio Serv, Inc. quarterly and annual Cost of Revenue in USD history and change rate from 30 Apr 2017 to 31 Oct 2025.
  • Pharma-Bio Serv, Inc. Cost of Revenue for the quarter ending 31 Oct 2025 was $1,400,701, a 13% decline year-over-year.
  • Pharma-Bio Serv, Inc. Cost of Revenue for the twelve months ending 31 Oct 2025 was $6,091,064, a 13% decline year-over-year.
  • Pharma-Bio Serv, Inc. annual Cost of Revenue for 2025 was $6,091,064, a 13% decline from 2024.
  • Pharma-Bio Serv, Inc. annual Cost of Revenue for 2024 was $6,993,241, a 41% decline from 2023.
  • Pharma-Bio Serv, Inc. annual Cost of Revenue for 2023 was $11,910,445, a 18% decline from 2022.
Source SEC data
View on sec.gov
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Change (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Change (%)

Pharma-Bio Serv, Inc. Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,091,064 $1,400,701 -$206,041 -13% 01 Aug 2025 31 Oct 2025 10-K 29 Jan 2026 2025 FY
Q2 2025 $6,297,105 $1,388,821 -$393,958 -22% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $6,691,063 $1,598,318 -$160,824 -9.1% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $6,851,887 $1,703,224 -$141,354 -7.7% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $6,993,241 $1,606,742 -$1,061,644 -40% 01 Aug 2024 31 Oct 2024 10-K 29 Jan 2026 2025 FY
Q2 2024 $8,054,885 $1,782,779 -$1,244,381 -41% 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025 2025 Q3
Q1 2024 $9,299,266 $1,759,142 -$1,457,557 -45% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q2
Q4 2023 $10,756,823 $1,844,578 -$1,153,622 -38% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q1
Q3 2023 $11,910,445 $2,668,386 -$861,171 -24% 01 Aug 2023 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $12,771,616 $3,027,160 -$434,629 -13% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $13,206,245 $3,216,699 -$534,713 -14% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q2
Q4 2022 $13,740,958 $2,998,200 -$776,321 -21% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q1
Q3 2022 $14,517,279 $3,529,557 -$568,815 -14% 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $15,086,094 $3,461,789 -$271,058 -7.3% 01 May 2022 31 Jul 2022 10-Q 14 Sep 2023 2023 Q3
Q1 2022 $15,357,152 $3,751,412 +$618 +0.02% 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q2
Q4 2021 $15,356,534 $3,774,521 +$601,322 +19% 01 Nov 2021 31 Jan 2022 10-Q 17 Mar 2023 2023 Q1
Q3 2021 $14,755,212 $4,098,372 +$431,027 +12% 01 Aug 2021 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $14,324,185 $3,732,847 -$691,304 -16% 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022 2022 Q3
Q1 2021 $15,015,489 $3,750,794 -$28,073 -0.74% 01 Feb 2021 30 Apr 2021 10-Q 14 Jun 2022 2022 Q2
Q4 2020 $15,043,562 $3,173,199 +$145,924 +4.8% 01 Nov 2020 31 Jan 2021 10-Q 17 Mar 2022 2022 Q1
Q3 2020 $14,897,638 $3,667,345 +$381,724 +12% 01 Aug 2020 31 Oct 2020 10-K 11 Feb 2022 2021 FY
Q2 2020 $14,515,914 $4,424,151 +$1,023,556 +30% 01 May 2020 31 Jul 2020 10-Q 14 Sep 2021 2021 Q3
Q1 2020 $13,492,358 $3,778,867 +$221,925 +6.2% 01 Feb 2020 30 Apr 2020 10-Q 14 Jun 2021 2021 Q2
Q4 2019 $13,270,433 $3,027,275 -$59,862 -1.9% 01 Nov 2019 31 Jan 2020 10-Q 17 Mar 2021 2021 Q1
Q3 2019 $13,330,295 $3,285,621 -$514,126 -14% 01 Aug 2019 31 Oct 2019 10-K 01 Feb 2021 2020 FY
Q2 2019 $13,844,421 $3,400,595 +$363,140 +12% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2020 Q3
Q1 2019 $13,481,281 $3,556,942 +$828,596 +30% 01 Feb 2019 30 Apr 2019 10-Q 15 Jun 2020 2020 Q2
Q4 2018 $12,652,685 $3,087,137 +$542,067 +21% 01 Nov 2018 31 Jan 2019 10-Q 16 Mar 2020 2020 Q1
Q3 2018 $12,110,618 $3,799,747 01 Aug 2018 31 Oct 2018 10-K 29 Jan 2020 2019 FY
Q2 2018 $3,037,455 -$14,575 -0.48% 01 May 2018 31 Jul 2018 10-Q 16 Sep 2019 2019 Q3
Q1 2018 $2,728,346 -$151,631 -5.3% 01 Feb 2018 30 Apr 2018 10-Q 14 Jun 2019 2019 Q2
Q4 2017 $2,545,070 01 Nov 2017 31 Jan 2018 10-Q 18 Mar 2019 2019 Q1
Q2 2017 $3,052,030 01 May 2017 31 Jul 2017 10-Q 14 Sep 2018 2018 Q3
Q1 2017 $2,879,977 01 Feb 2017 30 Apr 2017 10-Q 14 Jun 2018 2018 Q2

Pharma-Bio Serv, Inc. Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $6,091,064 -$902,177 -13% 01 Nov 2024 31 Oct 2025 10-K 29 Jan 2026 2025 FY
2024 $6,993,241 -$4,917,204 -41% 01 Nov 2023 31 Oct 2024 10-K 29 Jan 2026 2025 FY
2023 $11,910,445 -$2,606,834 -18% 01 Nov 2022 31 Oct 2023 10-K 29 Jan 2025 2024 FY
2022 $14,517,279 -$237,933 -1.6% 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2021 $14,755,212 -$142,426 -0.96% 01 Nov 2020 31 Oct 2021 10-K 30 Jan 2023 2022 FY
2020 $14,897,638 +$1,567,343 +12% 01 Nov 2019 31 Oct 2020 10-K 11 Feb 2022 2021 FY
2019 $13,330,295 +$1,219,677 +10% 01 Nov 2018 31 Oct 2019 10-K 01 Feb 2021 2020 FY
2018 $12,110,618 +$2,655,344 +28% 01 Nov 2017 31 Oct 2018 10-K 29 Jan 2020 2019 FY
2017 $9,455,274 01 Nov 2016 31 Oct 2017 10-K 29 Jan 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.